Androgen deprivation in prostate cancer: benefits of home-based resistance training
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2198-9761
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Androgen deprivation in prostate cancer: benefits of home-based resistance training ; volume:6 ; number:1 ; day:14 ; month:12 ; year:2020 ; pages:1-12 ; date:12.2020
Sports medicine - open ; 6, Heft 1 (14.12.2020), 1-12, 12.2020
- Urheber
-
Lam, Teresa
Cheema, Birinder
Hayden, Amy
Lord, Stephen R.
Gurney, Howard
Gounden, Shivanjini
Reddy, Navneeta
Shahidipour, Haleh
Read, Scott
Stone, Glenn
McLean, Mark
Birzniece, Vita
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40798-020-00288-1
- URN
-
urn:nbn:de:101:1-2021012118552390440389
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lam, Teresa
- Cheema, Birinder
- Hayden, Amy
- Lord, Stephen R.
- Gurney, Howard
- Gounden, Shivanjini
- Reddy, Navneeta
- Shahidipour, Haleh
- Read, Scott
- Stone, Glenn
- McLean, Mark
- Birzniece, Vita
- SpringerLink (Online service)
Ähnliche Objekte (12)
Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer
Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
PTP1B regulates lymphocytes responses androgen deprivation
Docetaxel in the management of PSA progression following primary androgen deprivation for prostate cancer
Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer
Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
PTP1B regulates lymphocytes responses androgen deprivation
Docetaxel in the management of PSA progression following primary androgen deprivation for prostate cancer
Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer
Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
PTP1B regulates lymphocytes responses androgen deprivation